Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Genmab (GMAB) Received its Third Buy in a Row
11:14am, Monday, 27'th Apr 2020
After RBC Capital and Morgan Stanley gave Genmab (NASDAQ:
GMAB
) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst
Ram Selvaraju
reiterated a
Buy
ratin
Lindbrook Capital LLC Has $32,000 Stake in Genmab A/S (NASDAQ:GMAB)
09:34am, Saturday, 25'th Apr 2020
Lindbrook Capital LLC trimmed its position in shares of Genmab A/S (NASDAQ:GMAB) by 47.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Excha
Were Hedge Funds Right About RingCentral Inc (RNG)?
08:19pm, Thursday, 23'rd Apr 2020
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Genmab A/S (NASDAQ:GMAB) Shares Sold by Bank of New York Mellon Corp
09:14am, Wednesday, 22'nd Apr 2020
Bank of New York Mellon Corp decreased its stake in Genmab A/S (NASDAQ:GMAB) by 1.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fir
Equities Analysts Set Expectations for Genmab A/S's FY2020 Earnings (NASDAQ:GMAB)
07:52am, Friday, 17'th Apr 2020
Genmab A/S (NASDAQ:GMAB) – Analysts at SunTrust Banks boosted their FY2020 EPS estimates for shares of Genmab A/S in a research report issued on Tuesday, April 14th. SunTrust Banks analyst A. Goonew
Companies in the
Healthcare sector have received a lot of coverage today as analysts
weigh in on Rhythm Pharmaceuticals (
RYTM
–
Research Report
), Genmab (
GMAB
–
Research Report
) and Mylan (
MY
Genmab (GMAB) Gets a Buy Rating from H.C. Wainwright
11:22am, Wednesday, 15'th Apr 2020
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report),
Should We Worry About Genmab A/S's (CPH:GMAB) P/E Ratio?
05:48am, Wednesday, 15'th Apr 2020
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll show how you can use...
The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 13.) * Chembio Diagnostics Inc (NASDAQ: CEMI)
Analysts Anticipate Genmab A/S (NASDAQ:GMAB) to Post $0.02 EPS
09:50am, Saturday, 11'th Apr 2020
Equities research analysts forecast that Genmab A/S (NASDAQ:GMAB) will report earnings per share (EPS) of $0.02 for the current fiscal quarter, Zacks reports. Three analysts have provided estimates fo
Cubist Systematic Strategies LLC Takes $537,000 Position in Genmab A/S (NASDAQ:GMAB)
09:10am, Friday, 10'th Apr 2020
Cubist Systematic Strategies LLC acquired a new position in shares of Genmab A/S (NASDAQ:GMAB) during the 4th quarter, Holdings Channel.com reports. The firm acquired 24,058 shares of the company’s
Genmab (GMAB) Receives a Buy from H.C. Wainwright
11:13am, Thursday, 09'th Apr 2020
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report),
RBC Capital Keeps a Buy Rating on Genmab (GMAB)
02:41am, Monday, 06'th Apr 2020
In a report issued on April 2,
Kennen MacKay
from RBC Capital maintained a
Buy
rating on Genmab (
GMAB
–
Research Report
), with a price target of
$27.00
. The company’s shares closed last Friday
Advisor Group Inc. Has $94,000 Holdings in Genmab A/S (NASDAQ:GMAB)
08:04am, Sunday, 05'th Apr 2020
Advisor Group Inc. grew its stake in shares of Genmab A/S (NASDAQ:GMAB) by 81.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund ow
Agenus At The Time Of The Coronavirus
07:30pm, Thursday, 02'nd Apr 2020
Agenus has a broad and deep pipeline into clinical development. The company is running two pivotal trials. AGEN1181 may have best in class properties that could
